|
|
Notice: NIH Consensus Development Conference: Lactose Intolerance and
Health; Notice Federal Register: January 15, 2010 (Volume 75, Number 10)
Page 2551-2552Agency: DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health
Notice is hereby given by the National Institutes of Health (NIH)
of the ``NIH Consensus Development Conference: Lactose Intolerance and
Health'' to be held February 22-24, 2010, in the NIH Natcher Conference
Center, 45 Center Drive, Bethesda, Maryland 20892. The conference will
begin at 8:30 a.m. on February 22 and 23 and at 9 a.m. on February 24,
and it will be open to the public.
Lactose intolerance is the inability to digest significant amounts
of lactose, a sugar found in milk and other dairy products. Lactose
intolerance is caused by a shortage of the enzyme lactase, which is
produced by expression of the lactase-phlorizin hydrolase gene by the
cells that line the small intestine. Lactase breaks milk sugar down
into two simpler forms of sugar called glucose and galactose, which are
then absorbed into the bloodstream. Infants of every racial and ethnic
group worldwide produce lactase and successfully digest lactose
provided by human milk or by infant formulas. However, by the time many
of the world's children reach the age of 3-4 years, expression of
intestinal lactase ceases. Most affected individuals, referred to as
lactase nonpersisters, in the United States belong to minority groups,
especially Asians, African Americans, Hispanics, Native Americans,
Alaskan Natives, and Pacific Islanders.
Consumption of lactose-containing products by lactase nonpersisters
may cause gas production, bloating, abdominal pain, and diarrhea. These
symptoms of lactose intolerance are caused by intestinal bacteria's
fermentation of undigested lactose and often cause individuals to avoid
lactose-containing products. Lactose intolerance can be diagnosed by
drinking one to two large glasses of milk after fasting and measuring
breath hydrogen levels a few hours later. Other diagnostic tools
include analyzing an intestinal biopsy sample or determining the
genetic makeup of the chromosomal region coding for lactase. However,
many individuals mistakenly ascribe symptoms of a variety of intestinal
disorders to lactose intolerance without undergoing testing. This
becomes intergenerational when self-diagnosed lactose-intolerant
parents place their children on lactose-restricted diets in the belief
that the condition is hereditary.
Healthcare providers are concerned that many lactose-intolerant
individuals are avoiding dairy products, which constitute a readily
accessible source of calcium and are fortified with vitamin D and other
nutrients. Therefore, these individuals may not be meeting recommended
intakes of these essential nutrients. Insufficient intakes of calcium
carry a risk of decreased bone mineral density. This may have effects
on bone health and increase the risk of fracture throughout the
lifecycle, especially in
[[Page 2552]]
postmenopausal women. Very low intake of vitamin D can lead to the
development of rickets, especially in those of African descent and
other highly pigmented individuals. Although milk alternative products
are typically fortified with vitamin D and other nutrients, they are
often more expensive and less widely available than conventional
products.
The public health burden from deficiencies attributable to lactose
intolerance is difficult to quantify. Additionally, it is challenging
to identify and manage lactase nonpersisters. Questions remain as to
the amount, if any, of lactose that can be tolerated by lactose
nonpersisters and how best to assist these individuals in meeting
recommended intakes. To examine these important issues, the Eunice
Kennedy Shriver National Institute of Child Health and Human
Development and the Office of Medical Applications of Research of the
National Institutes of Health will convene a Consensus Development
Conference from February 22 to 24, 2010, to assess the available
scientific evidence related to the following questions:
What is the prevalence of lactose intolerance, and how
does this prevalence differ by race, ethnicity, and age?
What are the health outcomes of dairy exclusion diets?
What amount of daily lactose intake is tolerable in
subjects with diagnosed lactose intolerance?
What strategies are effective in managing individuals with
diagnosed lactose intolerance?
What are the future research needs for understanding and
managing lactose intolerance?
An impartial, independent panel will be charged with reviewing the
available published literature in advance of the conference, including
a systematic literature review commissioned through the Agency for
Healthcare Research and Quality. The first day and a half of the
conference will consist of presentations by expert researchers and
practitioners and open public discussions. On Wednesday, February 24,
the panel will present a statement of its collective assessment of the
evidence to answer each of the questions above. The panel will also
hold a press telebriefing to address questions from the media. The
draft statement will be published online later that day, and the final
version will be released approximately six weeks later. The primary
sponsors of this meeting are the NIH Eunice Kennedy Shriver National
Institute of Child Health and Human Development and the NIH Office of
Medical Applications of Research.
Advance information about the conference and conference
registration materials may be obtained from the NIH Consensus
Development Program Information Center by calling 888-644-2667 or by
sending e-mail to consensus@mail.nih.gov. The Information Center's
mailing address is P.O. Box 2577, Kensington, Maryland 20891.
Registration information is also available on the NIH Consensus
Development Program Web site at http://consensus.nih.gov.
Please Note: The NIH has instituted security measures to ensure
the safety of NIH employees, guests, and property. All visitors must
be prepared to show a photo ID upon request. Visitors may be
required to pass through a metal detector and have bags, backpacks,
or purses inspected or x-rayed as they enter NIH buildings. For more
information about the security measures at NIH, please visit the Web
site at http://www.nih.gov/about/visitorsecurity.htm.
Dated: January 7, 2010.
Raynard S. Kington,
Deputy Director, National Institutes of Health.
[FR Doc. 2010-672 Filed 1-14-10; 8:45 am]
BILLING CODE 4140-01-P |